SCHEMBL2976136

SCHEMBL2976136

COc1ccc(NC2=C(C)C(=O)CC2)cc1OCCC1Cc2ccccc2C1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.46
HTT P42858 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
TSHR P16473 2/20 0.46
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
PDE4B Q07343 2/20 0.41
ALDH1A1 P00352 2/20 0.35
POLB P06746 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
HIF1A Q16665 1/20 0.35
BRD4 O60885 1/20 0.35
C5AR1 P21730 1/20 0.35
QPCT Q16769 1/20 0.34
IDO1 P14902 1/20 0.34
TAAR1 Q96RJ0 1/20 0.34
PDE4A P27815 1/20 0.34
PDE4C Q08493 1/20 0.34
PDE4D Q08499 1/20 0.34
NPC1 O15118 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2981396 0.94 LMNA (0.40) LMNAHTTSMN1; SMN2TSHRKMT2A
SCHEMBL2969685 0.82 TSHR (0.46) LMNAHTTTSHRKMT2AMEN1
SCHEMBL2979730 0.82 LMNA (0.51) LMNAHTTSMN1; SMN2TSHRKMT2A
SCHEMBL2976571 0.81 LMNA (0.50) LMNAHTTSMN1; SMN2TSHRKMT2A
SCHEMBL2979742 0.81 HTT (0.56) LMNAHTTSMN1; SMN2TSHRKMT2A
SCHEMBL2974579 0.80 LMNA (0.52) LMNAHTTSMN1; SMN2TSHRKMT2A
SCHEMBL2981052 0.78 LMNA (0.50) LMNAHTTSMN1; SMN2TSHRKMT2A
SCHEMBL2970130 0.78 LMNA (0.50) LMNAHTTSMN1; SMN2TSHRKMT2A
SCHEMBL2980586 0.77 LMNA (0.45) LMNAHTTSMN1; SMN2TSHRKMT2A
SCHEMBL2979724 0.76 PDE4B (0.45) LMNAHTTSMN1; SMN2TSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7772258-B2 Agent for treatment of allergic eye disease NIKKEN CHEMICALS CO., LTD. (JP) 2010-08-10 US disclosed
US-20080306163-A1 AGENT FOR TREATMENT OF ALLERGIC EYE DISEASE NIKKEN CHEMICALS CO., LTD. 2008-12-11 US disclosed
EP-0994100-B1 3-ANILINO-2-CYCLOALKENONE DERIVATES NIKKEN CHEMICALS CO LTD (JP) 2006-08-30 EP disclosed
EP-1410795-A1 REMEDIES FOR ALLERGIC EYE DISEASES Nikken Chemicals Company, Limited (JP) 2004-04-21 EP disclosed
US-6235736-B1 ANTIINFLAMMATORY AGENTS NIKKEN CHEMICALS CO., LTD. (JP) 2001-05-22 US disclosed
EP-0994100-A1 3-ANILINO-2-CYCLOALKENONE DERIVATES Nikken Chemicals Company, Limited (JP) 2000-04-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306163-A1 AGENT FOR TREATMENT OF ALLERGIC EYE DISEASE HRH4, HRH3, HRH2 LMNA 4304/4885HTT 2612/4885SMN1; SMN2 4826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.